Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gastroesophageal Reflux 2Barrett Esophagus 2Zollinger-Ellison Syndrome 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × YF 476 × Clear all
NCT01298999 2021-11-23

Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

Columbia University

Phase 2 Completed
27 enrolled 16 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus, Gastroesophageal Reflux

NCT02597712 2021-04-12

YF476 in Barrett's Esophagus

Trio Medicines Ltd.

Phase 2 Completed
27 enrolled 15 charts
Gastrointestinal

Barrett Esophagus, Gastroesophageal Reflux

NCT02454075 2021-01-29

YF476 and Type II Gastric Carcinoids

Trio Medicines Ltd.

Phase 2 Terminated
3 enrolled 11 charts

Zollinger-Ellison Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡